The purpose of the ReSPECT-GBM Clinical Trial is to assess the safety, tolerability, and distribution of a new medication, rhenium (186Re) obisbemeda, in adults with recurrent glioblastoma after standard surgical, radiation, and/or chemotherapy treatment. ReSPECT-GBM is supported by the U.S. National Institutes of Health / National Cancer Institute.
NATIONAL TRIAL REFERENCE NUMBER
When speaking with your physician, please have the national trial reference number available.
Patients Treated to Date
- All patients who enroll in the trial will receive medication while on the study.
- All patients will receive a single treatment of rhenium (186Re) obisbemeda.
- Phase 1: A Phase 1 study of a new medication is usually the first that involves human volunteers who have the disease or condition the investigational medicine is designed to treat. The primary objective of Phase 1 studies is to identify the highest dose of the new medication that can be safely given without serious side effects.
- Phase 2: If a new medication is found to be reasonably safe in a Phase 1 study, it can then be evaluated in a Phase 2 study to determine if it works. Doctors will assess whether the new medication provides a specific benefit or response, such as tumor shrinkage, improved quality of life, or longer patient survival.
- Actual Study Start: June 3, 2015
- Estimated Primary Completion: January 2025 (the date that the last participant in a clinical study was examined or received an intervention and that data for the primary outcome measure were collected)
- Estimated Study Completion: January 2025 (the date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events, that is, the last participant’s last visit).
Plus Therapeutics is evaluating rhenium (186Re) obisbemeda, a novel radiotherapy for brain cancer patients, in the U.S. NIH-supported ReSPECT-GBM Phase 2 clinical trial.
Watch now to learn more.
Only a qualified healthcare professional can determine whether or not you are eligible to participate in a clinical trial. However, this information may be beneficial in initiating a conversation with your physician. Patient reimbursement of up to $599 for time and travel is available. Healthy volunteers are not needed.
Adults, 18 Years and Older
Able to undergo a MRI scan
Have not taken Avastin (bevacizumab)
There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.
Andrew Brenner, M.D., Ph.D.
UT Health San Antonio
Mays Cancer Center
SPECIALTIES: MEDICAL ONCOLOGY, INTERNAL MEDICINE
A specialist in both breast cancer and malignancies of the brain and spinal cord, Andrew Brenner, M.D., Ph.D., not only focuses on clinical management, but also on the development of novel therapies to treat breast cancers and central nervous system tumors.
A graduate of Texas A&M University, he earned his bachelor’s degree in biochemistry and went on to earn his doctorate in biological science and tumor biology at The University of Texas M.D. Anderson Cancer Center – Science Park. His doctoral thesis focused on the role of the cyclin dependent kinase inhibitor p16INK4a in mammary tumorigenesis and immortilization. Dr. Brenner’s current interests have transitioned from cell cycle to the effect of hypoxia on chemokines and escape from antiangiogenics and the role of obesity in promoting breast tumorigenesis.
Dr. Brenner received his medical degree from the Texas Tech University Health Science Center and completed a residency in internal medicine at Scott and White Hospital in Lubbock. He completed his fellowship in hematology and medical oncology at the UT Health San Antonio.
Toral Patel, M.D.
UT Southwestern Medical Center
Peter O’Donnell Jr. Brain Institute
SPECIALTIES: NEUROLOGICAL SURGERY, SKULL BASE TUMORS, NEUROLOGICAL DISORDERS
Toral Patel, M.D., is an Assistant Professor in UT Southwestern Medical Center’s nationally ranked Department of Neurological Surgery, where she specializes in brain tumor surgery.
Dr. Patel received her undergraduate degree in biomedical engineering from Johns Hopkins University and earned her medical degree at UT Southwestern Medical School. She completed an internship in general surgery at Yale-New Haven Hospital, followed by a residency in neurological surgery, serving as Chief Resident. She then received advanced training in neurosurgical oncology through a fellowship at Memorial Sloan Kettering Cancer Center before returning to UT Southwestern as a faculty member in 2014.
Dr. Patel’s research has garnered numerous awards, including the William F. Collins Resident Research Award, a Seed Grant from the American Medical Association, the UT Southwestern Medical Student Summer Research Award, the Louis E. Goodman Award, and the Johns Hopkins University Department of Biomedical Engineering Undergraduate Research Award. She currently holds a patent titled “Highly penetrative nanocarriers for treatment of CNS disease” for her research into how nanoparticles can be used to carry drugs directly to the site of brain tumors.
Dr. Patel is a member of the Society for Neuro-Oncology, the American Medical Association, the American College of Surgeons, the Congress of Neurological Surgeons, and the American Association of Neurological Surgeons.
She was included in D Magazine‘s Best Doctors list for 2018.
Jeffrey Weinberg, M.D.
UT MD Anderson Cancer Center
Anne C. Brooks Brain and Spine Center
SPECIALTIES: PRIMARY AND METASTATIC BRAIN TUMORS, SPINAL CORD TUMORS, STEREOTACTIC RADIOSURGERY
Dr. Jeffrey Weinberg is currently a Professor of Neurosurgery, Deputy Chair and Vice-Chair of Clinical Operations in The Department of Neurosurgery at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is also the Director of the Intraoperative MRI Program.
Dr. Weinberg is a leader in the field of the Neurosurgical Oncology with particular knowledge about intraoperative MRI and technical expertise in surgical management of primary and metastatic brain tumors, spinal cord tumors and stereotactic radiosurgery. He has received various honors which include Excellence in Research Mentorship from the University of Texas Center for Biomedical Engineering, Houston, TX; the Excellence in Teaching Award from the University of Texas Center for Biomedical Engineering for three consecutive years, Top Doctor’s Designation by Castle Connolly and US News and World Report and most recently the MD Anderson Physician Referral Service Sam Hassenbusch Leadership and Institutional Service Award.
Dr. Weinberg is the Chair of the Peri-operative Value Analysis Team; President of the Intraoperative Imaging Society; past President of the Texas Association of Neurological Surgeons; Website Chair for the Joint Tumor Section of the AANS and CNS.
He has published more than 100 manuscripts in peer-reviewed journals and has authored 8 book chapters.
There are currently 3 clinical trial locations in the United States that are actively screening and enrolling patients.
Please visit this website regularly for updates as new locations are added.
UT Health Science Center
UT Southwestern Medical Center
UT MD Anderson Cancer Center
What Can You Do Next?
Participating in a clinical trial is an important decision. If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.
Discuss With Your Physician
Anyone participating in a clinical trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your physician first.
Print, save, or email this page to your physician to discuss at your next visit.
Be sure to have National Trial Reference Number NCT01906385 available.
Contact A Trial Coordinator
A trial coordinator is a specialized researcher who supports the management and coordination of clinical research studies. If you are interested in participating in a clinical trial, you may call a trial coordinator directly at one of the trial locations below.
UT Health Science Center
UT Southwestern Medical Center
January 18, 2023
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the first patient has been dosed in the ReSPECT-GBM Phase 2b dose expansion clinical trial evaluating rhenium (186Re) obisbemeda for the treatment of recurrent glioblastoma (GBM).
November 19, 2022
Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
ReSPECT-GBM clinical trial of rhenium (186Re) obisbemeda in recurrent glioblastoma continues to demonstrate safety and overall survival correlates with radiation dose to tumor. ReSPECT-GBM Phase 2 trial enrollment has begun.
September 12, 2022
Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022
August 13, 2022
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
June 13, 2022
Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
November 18, 2021
Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting
August 21, 2021
Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer
July 22, 2021
Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT™-GBM Trial
June 16, 2021
Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial
December 15, 2020
Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial
December 1, 2020
Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center
November 19, 2020
Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
November 13, 2020
Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial Update
October 29, 2020
Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT™ Glioblastoma Trial
October 2, 2020
Plus Therapeutics Announces Brain Cancer Clinical Advisory Team
October 1, 2020
ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting
September 15, 2020
Plus Therapeutics Receives Fast Track Designation From FDA for Its Novel Glioblastoma Treatment
September 1, 2020
Plus Therapeutics, Inc. receives FDA Orphan Drug Designation for its Novel Glioblastoma Treatment
July 28, 2020
Plus Therapeutics Completes Fifth Dose Escalation Cohort of the ReSPECT™ Glioblastoma Clinical Trial and Expands Trial Sites
May 12, 2020
Plus Therapeutics Announces Patient-Focused Presentation Supporting Brain Tumor Awareness Month
Brenner, Andrew et al. “Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: The ReSPECT Phase 1 Trial.” Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Pages vi65-vi66.
Brenner, Andrew et al. “High Absorbed Doses of Rhenium-186 NanoLiposomes (RNL) in Recurrent GBM: A Phase 1 Study.” Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii186.
Brenner, Andrew et al. “Safety & Feasibility of Rhenium-186 Nanoliposomes (186RNL) in Recurrent Glioma: the ReSPECT Phase 1 Trial.” 2022 Annual Conference on CNS Clinical Trials & Brain Metastases.
Floyd, John et al. “Image-Guided Rhenium-186 NanoLiposome (186RNL) Brachytherapy in the Treatment of Recurrent Glioblastoma: Technique, Image Analysis, Dosimetry, and Monitoring.” 2021 ASTRO Annual Meeting.
Brenner, Andrew et al. “Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT Phase 1 Trial.” E-Poster, 2021 American Society of Clinical Oncology Annual Meeting, June 4-8, 2021.
Brenner, Andrew et al. “Safety and Feasibility of Rhenium-186 NanoLiposomes (RNL) in Recurrent GBM: the ReSPECT Phase 1 Trial.” E-Poster, 2020 Society for Neuro-Oncology Annual Meeting, November 19-21, 2020.
Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1/2a Trial, EANM Congress, October 19, 2022
Note: all external links
- American Brain Tumor Association
- American Cancer Society
- Brain Tumor Network
- Dictionary of Cancer Terms
- End Brain Cancer Initiative
- MedlinePlus (NIH)
- National Brain Tumor Society
- National Cancer Institute
- National Comprehensive Cancer Network
- Support Groups Listing
- The Brain Tumour Charity
- Trial Connect
- Voices Against Brain Cancer